Sepsis, September 18 edition

Using spatial metabolomics and proteomics, the study mapped metabolic and protein changes across kidney regions during sepsis-associated acute kidney injury. ARG2 was increased in renal tubular cells and macrophages, and pharmacologic inhibition or renal tubule-specific knockdown improved renal function and reduced tubular lipid accumulation, apparently through restoration of PPARγ signaling. Human kidney organoids provided additional support for the mechanism.

Impact: This study identifies a spatially defined metabolic mechanism in sepsis-associated acute kidney injury and provides convergent in vivo, cellular, and organoid evidence for ARG2 as a therapeutic target. It moves beyond descriptive biomarkers toward a testable intervention strategy.

Clinical Implications: ARG2 inhibition could become a strategy for preventing or treating sepsis-associated acute kidney injury, but safety, selectivity, dosing, and efficacy must be established in clinically relevant animal models and prospective human studies before clinical use.

Future Directions: Future studies should validate ARG2 inhibition in multiple clinically relevant sepsis models, define therapeutic timing and dosing, assess effects on host defense and systemic metabolism, and determine whether ARG2-related signatures identify patients most likely to benefit.

The study developed a flow-cytometry assay for nuclear-membrane CD63 (nmCD63), a marker of azurophilic granule fusion with the neutrophil nuclear membrane during early neutrophil extracellular trap formation. Its diagnostic cutoffs and combined models were evaluated in a two-center prospective cohort with independent external validation, directly addressing the need for biomarkers of early reversible sepsis biology.

Impact: This paper translates a defined cellular event in neutrophil biology into a potentially deployable clinical assay. The prospective multicenter design and external validation increase confidence that nmCD63 could complement current sepsis diagnosis and risk assessment, although the truncated abstract does not provide the numerical performance estimates.

Clinical Implications: If validated in larger and more diverse populations, nmCD63 could support earlier adjunctive sepsis diagnosis and prognostic stratification, particularly when conventional infection and organ dysfunction markers are equivocal. It should not yet replace clinical assessment or established biomarkers.

Future Directions: Future work should report complete diagnostic and prognostic performance, test assay harmonization across laboratories, compare nmCD63 with monocyte HLA-DR and established sepsis biomarkers, and evaluate whether serial measurements can guide treatment or identify reversible disease trajectories.

TMEM175 expression was reduced in peripheral blood mononuclear cells from septic patients, and pharmacologic inhibition of TMEM175 worsened bacterial burden and mortality in a cecal ligation and puncture mouse model. In macrophages, TMEM175 deficiency impaired bacterial clearance without reducing initial phagocytic uptake, indicating a defect in intracellular processing. The mechanism involved transcriptional regulation of cathepsins, impaired lysosomal function, and suppression of PI3K-Akt-dependent inflammatory cytokine production.

Impact: The study identifies TMEM175 as a previously underappreciated link between lysosomal homeostasis and antibacterial macrophage function in sepsis. By separating phagocytic uptake from subsequent bacterial killing, it provides a mechanistic explanation for impaired host defense and a potential target for immune-supportive therapy.

Clinical Implications: TMEM175-related pathways may become targets for restoring macrophage bacterial killing in sepsis, but direct TMEM175 inhibition appears harmful in the tested model. Therapeutic development should therefore focus on context-specific modulation rather than nonspecific blockade.

Future Directions: Future research should define how TMEM175 activity changes across sepsis stages and immune phenotypes, test selective activators or pathway-normalizing interventions, validate findings in human macrophages and multiple infection models, and assess effects on antimicrobial therapy and organ injury.